← United States · Coverage record
US · SEC FORM 4
Attovia Therapeutics, Inc.
ATTO · Nasdaq · CIK 0002058707 · Healthcare · Biotechnology
INSIDER SIGNAL
85.1 / 100
6 buyers · 13 purchase transaction lines · $72.9M gross purchase
WHY THIS SIGNAL?
Buyer breadthStrong
Purchase sizeStrong
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy
Each bar shows the contribution to the current score; the weights and formula stay unchanged.
Cluster+35.0 / 35
Purchase size+24.4 / 25
Role+14.0 / 20
Recency+3.0 / 10
Conviction+8.8 / 10
What is holding the score back?
- ⚠ Role scores low · most senior buyer: Other (CEO, chair and 10% owners score lowest)
- ⚠ Purchase activity is becoming less recent
- ✓ Cluster breadth is broad · 4+ insiders
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
AprMayJunJulAugSepOct
WALSH COLINDirector
●●▼▼○○●●
Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P.Other
●●▼▼○○●●
venBio Global Strategic Fund IV, L.P.TenPercentOwner
○●
Green Jeremy; Redmile Biopharma Investments III, L.P.; Redmile Group, LLCTenPercentOwner
○●
SanofiTenPercentOwner
○●
FHMLS XI, L.L.C.; FHMLS XI, L.P.; Frazier Life Sciences XI, L.P.TenPercentOwner
○●
● Purchase▼ Sale○ Other
Showing the six most active owners; 1 additional owner(s) remain in Form 4 evidence.
Purchase breadth & concentration
QUALIFYING BUYERS6
PURCHASE CONCENTRATION28%Largest buyer: WALSH COLIN · $20.6M
CLUSTER BUYING · 15D6 insidersPeak activity: 2026-08-05–2026-08-06
Roles in the peak window: Director, Other, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.
SIGNAL HISTORY
85.1 / 100
Latest recorded score
↓ -0.1 ptsversus the previous recorded snapshot
- 85.4
- 85.3
- 85.3
- 85.2
- 85.1
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
Recent Form 4 activity
13Purchases
88Sales
18Other Form 4 lines
9SEC filings · 365 days
BUYING13 qualifying P line(s) · 180 days
SELLING88 sale line(s) · context only
OTHER18 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- -28.1%
- 3M
- —
- 6M
- —
- 12M
- —
Volatility & liquidity
- Volatility
- 81.1%
- Beta
- —
- Avg daily value
- USD 7.3M
Valuation
- Market cap
- USD 740.0M
- P/E
- —
Fundamentals
- Profit margin
- —
- ROE
- —
- Industry
- Biotechnology
Market data
Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-31 · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 1,649,612
- Previous report
- 831,090
- Avg daily volume
- 553,841
- Days to cover
- 3.0
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | WALSH COLIN | Purchase (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC filing ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | Purchase (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC filing ↗ |
| 2026-08-06 | WALSH COLIN | Purchase (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC filing ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | Purchase (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC filing ↗ |
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. | Purchase (P) | Common Stock | 382,352 | USD 17.00 | USD 6,499,984 | SEC filing ↗ |
| 2026-08-06 | Sanofi | Purchase (P) | Common Stock | 300,000 | USD 17.00 | USD 5,100,000 | SEC filing ↗ |
| 2026-08-06 | Green Jeremy; Redmile Biopharma Investments III, L.P.; Redmile Group, LLC | Purchase (P) | Common Stock | 600,000 | USD 17.00 | USD 10,200,000 | SEC filing ↗ |
| 2026-08-06 | FHMLS XI, L.L.C.; FHMLS XI, L.P.; Frazier Life Sciences XI, L.P. | Purchase (P) | Common Stock | 588,235 | USD 17.00 | USD 9,999,995 | SEC filing ↗ |
| 2026-08-05 | WALSH COLIN | Purchase (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC filing ↗ |
| 2026-08-05 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | Purchase (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC filing ↗ |
| 2026-08-05 | WALSH COLIN | Purchase (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC filing ↗ |
| 2026-08-05 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | Purchase (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC filing ↗ |
Form 4 evidence
119 transaction lines in the latest 365-day window; 119 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | WALSH COLIN | Purchase (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC filing ↗ |
| 2026-08-06 | WALSH COLIN | C (C) | Common Stock | 2,435,632 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | Purchase (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC filing ↗ |
Show recent Form 4 evidence (25 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | WALSH COLIN | Purchase (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC filing ↗ |
| 2026-08-06 | WALSH COLIN | C (C) | Common Stock | 2,435,632 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | Purchase (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC filing ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | C (C) | Common Stock | 2,435,632 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-06 | WALSH COLIN | Purchase (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC filing ↗ |
| 2026-08-06 | WALSH COLIN | C (C) | Common Stock | 2,435,632 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | Purchase (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC filing ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | C (C) | Common Stock | 2,435,632 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. | Purchase (P) | Common Stock | 382,352 | USD 17.00 | USD 6,499,984 | SEC filing ↗ |
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. | C (C) | Common Stock | 3,799,015 | USD — | USD — | SEC filing ↗ |
| 2026-08-06 | Deep Track Biotechnology Master Fund, Ltd.; Deep Track Capital, LP; KROIN DAVID | C (C) | Common Stock | 1,957,138 | USD — | USD — | SEC filing ↗ |
| 2026-08-06 | Sanofi | Purchase (P) | Common Stock | 300,000 | USD 17.00 | USD 5,100,000 | SEC filing ↗ |
| 2026-08-06 | Sanofi | C (C) | Common Stock | 782,855 | USD — | USD — | SEC filing ↗ |
| 2026-08-06 | Green Jeremy; Redmile Biopharma Investments III, L.P.; Redmile Group, LLC | Purchase (P) | Common Stock | 600,000 | USD 17.00 | USD 10,200,000 | SEC filing ↗ |
| 2026-08-06 | Green Jeremy; Redmile Biopharma Investments III, L.P.; Redmile Group, LLC | C (C) | Common Stock | 782,854 | USD — | USD — | SEC filing ↗ |
| 2026-08-06 | FHMLS XI, L.L.C.; FHMLS XI, L.P.; Frazier Life Sciences XI, L.P. | Purchase (P) | Common Stock | 588,235 | USD 17.00 | USD 9,999,995 | SEC filing ↗ |
| 2026-08-06 | FHMLS XI, L.L.C.; FHMLS XI, L.P.; Frazier Life Sciences XI, L.P. | C (C) | Common Stock | 5,490,629 | USD — | USD — | SEC filing ↗ |
| 2026-08-05 | WALSH COLIN | Sale (S) | Common Stock | 105,607 | USD 21.28 | USD 2,247,248 | SEC filing ↗ |
| 2026-08-05 | WALSH COLIN | Purchase (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC filing ↗ |
| 2026-08-05 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | Sale (S) | Common Stock | 105,607 | USD 21.28 | USD 2,247,248 | SEC filing ↗ |
| 2026-08-05 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | Purchase (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC filing ↗ |
| 2026-08-05 | WALSH COLIN | Sale (S) | Common Stock | 105,607 | USD 21.28 | USD 2,247,248 | SEC filing ↗ |
| 2026-08-05 | WALSH COLIN | Purchase (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC filing ↗ |
| 2026-08-05 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | Sale (S) | Common Stock | 105,607 | USD 21.28 | USD 2,247,248 | SEC filing ↗ |
| 2026-08-05 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | Purchase (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | ATTO |
| CIK | 0002058707 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 119 transaction lines from 2026-08-05 to 2026-08-06 13 P purchase lines · 88 S sale lines · 18 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.